Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$99.26

-0.63 (-0.63%)

09:27
10/10/16
10/10
09:27
10/10/16
09:27

TESARO price target raised to $128 from $122 at RBC Capital

RBC Capital analyst Adnan Butt raised his price target on TESARO after ovarian cancer patients taking the company's Niraparib drug responded better than expected. Butt said that the drug benefited the patients regardless of BRCA or HRD biomarker status. He keeps an Outperform rating on the stock.

  • 06

    Nov

  • 11

    Jan

TSRO Tesaro
$99.26

-0.63 (-0.63%)

10/10/16
LEER
10/10/16
NO CHANGE
Target $115
LEER
Outperform
TESARO price target raised to $115 after niraparib data at Leerink
Leerink analyst Seamus Fernandez said full results of TESARO's Phase 3 NOVA trial for niraparib as second-line maintenance for ovarian cancer presented at the ESMO meeting are strong enough to warrant approval in the overall patient population regardless of BRCAmut or HRD status. He increased his probability of approval in non-gBRCA/HRD-negative patients to 70% in the U.S., from 0%, and to 50% in the EU, from 0%. He raised his price target on TESARO shares to $115 from $108 per share and keeps an Outperform rating on the stock.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Strong Buy
TESARO price target raised to $120 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.
10/10/16
FBCO
10/10/16
NO CHANGE
Target $122
FBCO
Outperform
TESARO price target raised to $122 on Niraparib data at Credit Suisse
Credit Suisse analyst Alethia Young raised TESARO's price target to $122 from $90 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. The analyst thinks niraparib has broad effects across the 2nd line ovarian population and would expect the label is broad. Young has an Outperform ratting n TESARO shares.
10/10/16
RAJA
10/10/16
NO CHANGE
Target $120
RAJA
Outperform
TESARO price target raised to $120 from $105 at Raymond James
Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating

TODAY'S FREE FLY STORIES

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:46
04/23/17
04/23
17:46
04/23/17
17:46
Earnings
C.R. Bard raises FY17 adjusted EPS to $11.65-$11.90 from $11.45-$11.75 »

EPS consensus $11.64.…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:43
04/23/17
04/23
17:43
04/23/17
17:43
Earnings
C.R. Bard sees Q2 adjusted EPS $2.75-$2.85, consensus $2.87 »

Sees Q2 revenue growth…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:41
04/23/17
04/23
17:41
04/23/17
17:41
Earnings
C.R. Bard reports Q1 adjusted EPS $2.87, consensus $2.65 »

Reports Q1 revenue…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:38
04/23/17
04/23
17:38
04/23/17
17:38
Hot Stocks
Becton Dickinson names Polen as president, says will lead Bard segment »

BD (BDX) announced the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

HCMLY

LafargeHolcim

$11.56

-0.1 (-0.86%)

17:32
04/23/17
04/23
17:32
04/23/17
17:32
Periodicals
LafargeHolcim CEO set to step down, FT reports »

LafargeHolcim CEO Eric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:30
04/23/17
04/23
17:30
04/23/17
17:30
Hot Stocks
Becton Dickinson outlines strategic highlights of C.R. Bard acquisition »

Expanding on the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

KLRE

KLR Energy Acquisition

$10.40

-0.02 (-0.19%)

17:29
04/23/17
04/23
17:29
04/23/17
17:29
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:23
04/23/17
04/23
17:23
04/23/17
17:23
Hot Stocks
BD sees forming third business segment, says Bard CEO to join board »

Commenting on its…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:20
04/23/17
04/23
17:20
04/23/17
17:20
Hot Stocks
BD sees high single-digit EPS accretion in FY19 »

"This financially…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:18
04/23/17
04/23
17:18
04/23/17
17:18
Hot Stocks
Becton Dickinson says expects to continue buyback suspension »

"BD expects to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:16
04/23/17
04/23
17:16
04/23/17
17:16
Hot Stocks
Becton Dickinson to acquire C.R. Bard in $24B cash and stock deal »

BD (BDX) and C. R. Bard…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:10
04/23/17
04/23
17:10
04/23/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Becton Dickinson, C.R. Bard »

Becton Dickinson to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

CS

Credit Suisse

$14.45

-0.09 (-0.62%)

17:07
04/23/17
04/23
17:07
04/23/17
17:07
Periodicals
Credit Suisse to determine capital raise plan after annual meeting, Reuters says »

Credit Suisse will make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$142.27

-0.17 (-0.12%)

17:04
04/23/17
04/23
17:04
04/23/17
17:04
Periodicals
Uber CEO ordered iPhone tracking, was scolded by Tim Cook, NYT says »

Beginning in 2014, ride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AVID

Avid Technology

$5.11

0.19 (3.86%)

, MSFT

Microsoft

$66.40

0.9 (1.37%)

16:30
04/23/17
04/23
16:30
04/23/17
16:30
Hot Stocks
Avid announces strategic cloud alliance with Microsoft »

Avid (AVID) announced it…

AVID

Avid Technology

$5.11

0.19 (3.86%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

15:44
04/23/17
04/23
15:44
04/23/17
15:44
Conference/Events
Wolfe Research utilities analyst holds an analyst/industry conference call »

Utilities Analyst…

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

ABUS

Arbutus Biopharma

15:10
04/23/17
04/23
15:10
04/23/17
15:10
Hot Stocks
Arbutus reports ARB-1467 study data, plans additional trial in 2H »

Arbutus Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

ACHN

Achillion

$3.64

-0.02 (-0.55%)

, JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

15:05
04/23/17
04/23
15:05
04/23/17
15:05
Hot Stocks
Achillion reports updated data from Phase 2 JNJ-4178 study »

Achillion Pharmaceuticals…

ACHN

Achillion

$3.64

-0.02 (-0.55%)

JNJ

Johnson & Johnson

$121.76

-0.11 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

BMY

Bristol-Myers

$53.48

0.04 (0.07%)

14:59
04/23/17
04/23
14:59
04/23/17
14:59
Hot Stocks
Bristol-Myers says '036 NASH study meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

14:52
04/23/17
04/23
14:52
04/23/17
14:52
General news
Breaking General news story  »

Fillon concedes as Le…

ALBO

Albireo Pharma

$20.66

-0.26 (-1.24%)

14:45
04/23/17
04/23
14:45
04/23/17
14:45
Hot Stocks
Albireo Pharma reports 'promising' A4250 data, sees Phase 3 trial start in 2H »

Albireo Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.